Oncobiologics (OTLK) Projected to Post Earnings on Thursday

Oncobiologics (NASDAQ:OTLK) is anticipated to release its Q2 2026 results before the market opens on Thursday, May 14th. Analysts expect Oncobiologics to post earnings of ($0.12) per share and revenue of $4.39 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, May 21, 2026 at 12:30 PM ET.

Oncobiologics (NASDAQ:OTLK) last posted its earnings results on Tuesday, February 17th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). The business had revenue of ($1.21) million during the quarter, compared to analysts’ expectations of $3.14 million. On average, analysts expect Oncobiologics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncobiologics Stock Performance

OTLK stock opened at $0.25 on Tuesday. The company has a market capitalization of $25.91 million, a price-to-earnings ratio of -0.09 and a beta of 0.32. The business’s 50 day moving average price is $0.30 and its two-hundred day moving average price is $0.87. Oncobiologics has a fifty-two week low of $0.16 and a fifty-two week high of $3.39.

Institutional Trading of Oncobiologics

Several institutional investors have recently added to or reduced their stakes in OTLK. AQR Capital Management LLC boosted its stake in Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after purchasing an additional 25,351 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Oncobiologics by 74.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after purchasing an additional 44,063 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Oncobiologics by 865.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after purchasing an additional 21,941 shares during the last quarter. 11.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Ascendiant Capital Markets cut their price target on Oncobiologics from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Chardan Capital restated a “neutral” rating on shares of Oncobiologics in a research note on Wednesday, February 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Oncobiologics in a research note on Friday, March 27th. Finally, HC Wainwright restated a “neutral” rating on shares of Oncobiologics in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $4.50.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.